• Home  / 
  • Biotech
  •  /  Affimed NV (NASDAQ:AFMD) AFM13 Shows Promising Results In CD30-Positive Cutaneous Lymphoma & Hodgkin’s Lymphoma Clinical Trials

Affimed NV (NASDAQ:AFMD) AFM13 Shows Promising Results In CD30-Positive Cutaneous Lymphoma & Hodgkin’s Lymphoma Clinical Trials

Affimed NV (NASDAQ:AFMD)’s AFM13 has shown promising results during the clinical trials of both CD30-positive cutaneous lymphoma and Hodgkin’s lymphoma. AFM13 is a bispecific antibody recruiting natural killer (NK) cells of the tumor in the vicinity. The announcement to this regard was made by the clinical-stage biopharmaceutical company recently.

The report says that in the case of CD30-positive cutaneous lymphoma, the AFMI13 treatment alone resulted in responses in two out of the three patients who were treated with its lowest dose. In the case of patients suffering from refractory or replaced Hodgkin’s lymphoma, the combination of Keytruda (pembrolizumab) and AFM13 were in itself considered safe and encouraged a response in around 89% patients including 44% patients giving a complete response.

In a press release, the CEO of Affimed, Adi Hoess stated that the company is extremely encouraged after finding these new data indicating that the first-in-class NK cell engager AFM13 has been successful at achieving clinically meaningful responses in both the single as well as in combination with a checkpoint inhibitor. The bispecific antibody targets the CD30 protein present in the cancer cells and the CD16A protein present in the NK cells.

Through this treatment, the NK cells are brought in the vicinity of the cancer cells thereby boosting their anti-cancer properties. Currently, Affimed is investigating AFM13 as a treatment option for lymphoma patients in which cancer cells produce the CD30 factor.

Clinical Data Reveals Impressive Results For AFM13

The currently ongoing investigator-sponsored Phase 1b/2a study is being tested in 18 patients suffering from CD30-positive T-cell cutaneous lymphoma who failed to get expected results for at least one prior line of therapy. The participants in the clinical trials will be given AFM13 in one of the six dosing regimens for determining the exact dose that can be best effective yet cause least side-effects.

The preliminary data from the first three patients participating in the trial receiving 1.5mg/kg once in a week for eight weeks consecutively revealed that the treatment received one partial response and one complete response and that it was completely safe.

About the author

Louisa Hendrickson

Hendrickson is the biotech writer for Investing News Center.

Click here to add a comment

Leave a comment: